failure analysis for update
TRANSCRIPT
Michael N. Helmus, Ph.D., [email protected]
Failure Analysis: Reevaluating Functional Requirements of Medical Devices
Failure Analysis: Reevaluating Functional Requirements of Medical Devices Invited Speaker, “Failure Analysis: Reevaluating Functional
Requirements of Medical Devices”, Opportunities for Next Generation Medical Devices,
Aug 5-7, 2008, Cleveland Clinic and ASM International.
New devices require diverse skills while utilizing biocompatible, biomechanical, bioactive, & nanoenabled mat'ls. http://tpx.sagepub.com/content/36/1/70.full.pdf+html These disruptive technologies will drive personalized medicine. http://www.iscpubs.com/Media/PublishingTitles/a0306hel.pdf Understanding the design process & failure analysis will facilitate & accelerate medical device development (M. N. Helmus, "Biomaterials in the design and reliability of medical devices", Kluwer & Landes Bioscience, 2003).
Let me help you with your development efforts (contact me for a special one day rate during Dec. 2010 ).
cell (508) 269 6021 fax (508) 519 [email protected]
Michael N. Helmus, Ph.D., Consultant
Medical Devices, Biomaterials, Drug Delivery, and Nanotechnology
(508) 767 0585
Michael N. Helmus, Ph.D., [email protected]
Agenda
• Introduction: Failure with focus on Materials and Design
• Biologic Reactions and Biocompatibility
• Biologic Issues
• Explant analysis paradigm
• Failures
• Personal anecdotes
• Commercial products
•Emerging Technologies and New Failure Modes
Michael N. Helmus, Ph.D., [email protected]
The Wall Street JournalThe Wall Street JournalFri. Aug 22, 2003Fri. Aug 22, 2003
Need for joint replacements at younger ages!
Michael N. Helmus, Ph.D., [email protected]
Michael N. Helmus, Ph.D., [email protected]
M. N. Helmus, ed., "Biomaterials in the design and reliability of medical devices", Kluwer Academic/Plenum Publishers and Landes Bioscience, NY, NY and Georgetown, TX, 2003.
BiocompatibilityBiocompatibility
Michael N. Helmus, Ph.D., [email protected]
FAILURE ANALYSIS AND THE MEDICAL DEVICE VALUE CHAIN
Ben
ch/
Anim
al
Testing
Distr
ibut
i
on Clinic
al
Applic
ati
onCompo
nen
ts/D
evic
es
Clinic
al
Trial
sRaw
Mat
eri
als
Technology Medicine
Develop IP Strategy: Composition of Matter ApplicationsFile IP
Redesign Redesign Post Market SurveillanceRedesign
Michael N. Helmus, Ph.D., [email protected]
Commercializing Technology
Medical Centers
Investors
Physician
IP Uncertainties
Competition
Resource Limits
Regulatory barriersReimburseme
ntLimited life-cycle
Technical Challenge/FAILURE
Michael N. Helmus, Ph.D., [email protected]
Endovascular Peripheral Grafts
ePTFE Vascular Graft
Textile Vascular GraftsCollagen Coated PET
Heart ValvesAnnuloplasty rings
Scaffolds for Tissue engineering
Mesh
for Hernia Repair
Biomaterials in Devices
CoilsBrain Aneurysms
Prosthetic joints
Bone repair - bone plates
Vertebroplasty -Bone cement filling of Compressed vertebrae
Implantable Defibrillator
Michael N. Helmus, Ph.D., [email protected]
Materials Selection Guide
Identify: • Predicate Devices • Corporate/Institutional Predicate Devices, Testing, and Regulatory Approvals (510(k)s, PMA’s, and NDA’s) • Corporate/Institutional Guidelines, Procedures and Protocols • FDA Guidelines, CEN Guidelines, and Standards (ASTM, ANSI, ISO) • Corporate/Institutional R&D Reports • Materials, Uses, Properties, ASTM and ISO Standards Develop an Approach for Selection and Testing
M. N. Helmus, ed., "Biomaterials in the design and reliability of medical devices", Kluwer Academic/Plenum Publishers and Landes Bioscience, NY, NY and Georgetown, TX, 2003.
Michael N. Helmus, Ph.D., [email protected]
MATERIALS SELECTION INDEVICE DESIGN AND TESTING
Functional Requirements
Prioritization of Requirements
Brain StormingMedical Literature and Patents Non-Medical Literature and
Patents
Networking
Design and Processing Approaches
Predicate Devices/Tissue/and Cell Processing and Failure Modes
Corporate/Institutional 510(k)s, PMA’s, NDA’s, Tissue
transplants
Michael N. Helmus, Ph.D., [email protected]
Identification of relevant standards/ guidelines and Test Methods
Corporate/Institutional Guidelines, Protocols, and Master FilesRegulatory: FDA, CEN
Standards Organizations: ISO, ANSI, AAMI, ASTM
Biomaterials, Scaffolds, Tissue, and Cell/Tissue Selection and Processing:
RequirementsBiomechanical, Physiochemical, Surface, Durability, Biostability,
Biocompatibility, Immunology (autografts, allografts, xenografts, and cellular engineering), Viability and Thromboresistance
Approach 1 Approach 2 Approach 3 Approach 4
Prototype Component Modeling/Processing and Testing
New Materials and Processes - YesExisting Data - No
Determine Sterilization/Antimicrobial Methods and Testing
Biocompatibility Screening
Michael N. Helmus, Ph.D., [email protected]
Michael N. Helmus, Ph.D., [email protected]
In Memory of Oscar Ratnoff
Hageman Factor (FXII) and Clotting Cascade
“Failure”of Blood to Clot in a Glass Tube
New UnderstandingFor Biomaterials andBlood ContactingDevices
Michael N. Helmus, Ph.D., [email protected]
Michael N. Helmus, Ph.D., [email protected]
M. N. Helmus, ed., "Biomaterials in the design and reliability of medical devices", Kluwer Academic/Plenum Publishers and Landes Bioscience, NY, NY and Georgetown, TX, 2003.
Michael N. Helmus, Ph.D., [email protected]
Michael N. Helmus, Ph.D., [email protected]
ISO 10993-1ISO 10993-2ISO 10993-3ISO 10993-4ISO 10993-5ISO 10993-6ISO 10993-7ISO 10993-8ISO 10993-9ISO 10993-10ISO 10993-11ISO 10993-12ISO 10993-13ISO 10993-14ISO 10993-15
ISO 10993-16ISO 10993-17
ISO 10993-18ISO 10993-19ISO 10993-20
Guidance on selection of testsAnimal welfare requirementsTests for genotoxicity, carcinogenicity, and reproductive toxicitySelection of tests for interactions with bloodTests for cytotoxicity: In vitro methodsTests for local effects after implantationEthylene oxide sterilization residualsWithdrawn: Clinical investigation of medical devicesEvaluation of biodegradation of medical devicesTests for irritation and sensitizationTests for systemic toxicitySample preparation and reference materialsIdentification and quantification of degradation products from polymersStatic test to quantify in vitro degradation of ceramicsIdentification and quantification of degradation products from metallic materials used in medical devicesToxicokinetic study design for degradation products and leachablesGlutaraldehyde and formaldehyde residues in industrially sterilized medical devices
Characterization of materials – EXHAUSTIVE EXTRACTIONPhysico-chemical, morphological and topographical characterization of materials Principles and methods for immunotoxicology testing of medical devices
INTERNATIONAL STANDARDS FOR MEDICAL DEVICES
Michael N. Helmus, Ph.D., [email protected]
Biocompatibility Issues of Biomaterials Synthetic Plastics, Engineering Plastics, Textiles, and
Hydrogels Extractables Hypersensitivity reactions (e.g. latex materials) 2 part systems and cytotoxic residuals Lipid uptake Hydrolytic stability Biostability Biodegradation by-products Calcification Sterilization residuals Fatigue and wear particulates Protein adsorption: hydrophilic, hydrogel and hydrophobic
M. N. Helmus, D. F. Gibbons, D. Cebon, "Biocompatibility: Meeting a key functional requirement of next-generation medical devices”, Toxicol Pathol 36 (1):70-80, 2008
Michael N. Helmus, Ph.D., [email protected]
Michael N. Helmus, Ph.D., [email protected]
Guidance for Industry and FDA Staff - Saline, Silicone Gel, and Alternative Breast Implants
Document issued on: November 17, 2006
This document supersedes “Guidance for Saline, Silicone Gel, and Alternative Breast Implants” dated February 11, 2003.
The draft of this document was issued on January 13, 2004.
http://www.fda.gov/cdrh/ode/guidance/1239.html
Michael N. Helmus, Ph.D., [email protected]
Michael N. Helmus, Ph.D., [email protected]
A design that considers rupture to be
inevitable in trauma would suggest that
a gel-like filler in any mammary prosthesis
must be inherently biocompatible.
Michael N. Helmus, Ph.D., [email protected]
Biodegradation
An alteration of the biomaterial or medical device involving loss of integrity or performancein a physiological or simulated environment.
Michael N. Helmus, Ph.D., [email protected]
Example Biostability
Polyurethanes
Poyesterurethanes - hydrolytically unstable
Polyetherurethances – ofter grades prone to oxidative enzyme degradation, e.g. 1) acute inflammation, 2) metal ion catalyzed in pacer leads
Polyureaurethanes - generally stables, high fatigue life, not thermally processable, I.e. solution cast
Polycarbonate urethanes - generally stable, low level of hydrolytic degradation possible.
Michael N. Helmus, Ph.D., [email protected]
M. N. Helmus, ed., "Biomaterials in the design and reliability of medical devices", Kluwer Academic/Plenum Publishers and Landes Bioscience, NY, NY and Georgetown, TX, 2003.
Michael N. Helmus, Ph.D., [email protected]
Biodegradables
Rate of biodegradation Surface vs. bulk Particulates Biodegradation by-products Biodeposition Tissue partitioning and excretion Effect of infection (acidic pH) or hematoma (basic pH) on
degradation rates Fatigue and wear particulates
Michael N. Helmus, Ph.D., [email protected]
BBiioollooggiiccaallllyy DDeerriivveedd MMaatteerriiaallss:: AArrtteerriieess,, vvaallvveess,, sskkiinn,, dduurraa--mmaatteerr,, bboonnee,, lliiggaammeennttss
Decellularization processes Viability of cells in fresh or Cryopreserved Allografts Cytotoxic preservatives Cross-linking Sterilizability and residuals Biodegradation Calcification Immune responses Biomechanical properties Infectious contamination- bacterial, viral, fungal, and
prion
Michael N. Helmus, Ph.D., [email protected]
Bioderived Macromolecules: eg albumin, Chitosans, collagen, gelatin, elastin, fibrin, hyaluronic acid,
phospholipids, silk Purity Extractables Hydrolysis & Biodegradation Hypersensitivity reactions Lipid uptake Sterilization residuals Calcification Inflammatory and immune responses Permeability Water content Degree of cross-linking Effect of cross-linking on inflammation, immune response, and
thrombogenicity Fatigue and wear particulates
Michael N. Helmus, Ph.D., [email protected]
Tissue and BiomoleculesTissue and Biomolecules
Collagen Impregnated
Vascular GraftPericardialHeart Valve
Uterine Sling -Repliform ® Tissue Regeneration Matrix, human dermis architecture with cells removed
Michael N. Helmus, Ph.D., [email protected]
Typical Bioprosthetic Failure Modes
Pericardial (stenosis)
Porcine (insufficiency & stenosis)
MN Helmus & CM Cunanan, “Mechanical and Bioprosthetic Heart Valves”, in Biomaterials for Artificial Organs, Woodhead Publishing, in Press 4Q 2010
Michael N. Helmus, Ph.D., [email protected]
1 7,008,591 Supercritical fluid extraction process for tissue preparation
2 6,964,682 Heart valve holder that resist suture looping
3 6,945,997 Heart valves and suture rings therefor
4 6,837,902 Methods of making bioprosthetic heart valves with strain matched leaflets
5 6,585,766 Cloth-covered stents for tissue heart valves
6 6,413,275 Apparatus for testing bioprosthetic heart valve leaflets
7 6,245,105 Method of testing bioprosthetic heart valve leaflets
8 6,102,944 Methods of tissue heart valve assembly
9 5,961,549 Multi-leaflet bioprosthetic heart valve
10 5,928,281 Tissue heart valves
11 5,880,242 Nonpolymeric epoxy compounds for cross linking biological tissue and
bioprosthetic grafts prepared thereby
In Memory of Ralph Kafesjian
An engineer and innovator inHeart valve design
Michael N. Helmus, Ph.D., [email protected]
Failure Analysis Bioprosthetic Valve: Stuck leaflets
Pericardial Heart valve removed shortly after implantation
Leaflets stuck together
Surgeon (outside US) suggested patient had antiphospholipid syndrome
- Coagulation resulted in stuck leaflets
Michael N. Helmus, Ph.D., [email protected]
Failure Analysis Bioprosthetic Valve: Stuck leaflets cont.
Operating rooms notes documented the use of fibrin sealant on the sewing ring to mitigate paravalvular leaking
Histopath on leaflets showed an acellular protein layer
PTAH staining was consistent with fibrin
Conclusion: fibrin sealant was responsible for the stuck leaflets
Michael N. Helmus, Ph.D., [email protected]
Nature Medicine Published online: 13 January 2008
Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart
Harald C Ott1, Thomas S Matthiesen2, Saik-Kia Goh2, Lauren D Black3, Stefan M Kren2, Theoden I Netoff3 & Doris A Taylor2,4
About 3,000 individuals in the United States are awaiting a donor heart; worldwide, 22 million individuals are living with heart failure. A bioartificial heart is a theoretical alternative to transplantation or mechanical left ventricular support. Generating a bioartificial heart requires engineering of cardiac architecture, appropriate cellular constituents and pump function. We decellularized hearts by coronary perfusion with detergents, preserved the underlying extracellular matrix, and produced an acellular, perfusable vascular architecture, competent acellular valves and intact chamber geometry. To mimic cardiac cell composition, we reseeded these constructs with cardiac or endothelial cells. To establish function, we maintained eight constructs for up to 28 d by coronary perfusion in a bioreactor that simulated cardiac physiology. By day 4, we observed macroscopic contractions. By day 8, under physiological load and electrical stimulation, constructs could generate pump function (equivalent to about 2% of adult or 25% of 16-week fetal heart function) in a modified working heart preparation.
Michael N. Helmus, Ph.D., [email protected]
Malone, J, et al, 1984
Acelullar vascular matrixWas proposed as a Vascular prosthesis
Early 1980’s
Michael N. Helmus, Ph.D., [email protected]
Evaluation for potential immunogenicity
2nd set rejection study in Baboons
acellular canine carotid artery implanted in baboon carotid for 3 weeks
accellular canine carotid implanted in contralateral baboon carotid
Histopath evidence of immune response
Michael N. Helmus, Ph.D., [email protected]
Explant analysis paradigm
Implant History—Device, Patient/Animal, Medication (Pre-, Peri- , Postoperative), Patient History, Removal history (revision, autopsy), Gross Photographs insitu and after removal (keeping device moist with saline and limiting time of exposure to air). Blood contacting devices can result in embolic episodes andorgans such as the brain, lungs, and kidneys are particularly important to evaluate for infarcts. Device removal and handling as described below.
Michael N. Helmus, Ph.D., [email protected]
Biologic Analyses – An Overlooked component of expant analysis
M. N. Helmus, ed., "Biomaterials in the design and reliability of medical devices", Kluwer Academic/Plenum Publishers and Landes Bioscience, NY, NY and Georgetown, TX, 2003.
Michael N. Helmus, Ph.D., [email protected]
Material Properties
Michael N. Helmus, Ph.D., [email protected]
Passive Coatings: eg Albumin, diamond-like, fluorocarbons, hydrogels, PVD, CVD
Adherence Wear Flaking Uniformity Sterilizability Shelf-life Durability Biostability Extractables Hypersensitivity Lipid uptake Calcification Sterilization residuals Fatigue
Michael N. Helmus, Ph.D., [email protected]
Bioactive Coatings (heparin, antimicrobials, cell adhesion peptides, surface charge) and Tissue Adhesives ( Collagen,
cyanoacrylates, fibrin glue, PEG) Degree of antithrombogenicity, cell adhesion & tissue binding Biostability Wear & Durability Uniformity Sterilizability Microbiologic contamination Shelf-life Calcification Immune responses Residuals Tissue Adhesives - Purity - Filtration sterilization - Cure time - Tissue Adhesion
Michael N. Helmus, Ph.D., [email protected]
Heparin Release Coating CVC Catheters
US5447724
Medical device polymer
HELMUS MICHAEL N; TOLKOFF M JOSHUA; RALEIGH CAROL L
HARBOR MEDICAL DEVICES INC
Michael N. Helmus, Ph.D., [email protected]
Michael N. Helmus, Ph.D., [email protected]
2.4x10-4mg/cm2 /hr
Michael N. Helmus, Ph.D., [email protected]
Case Study: Processing and heparin release
Particulate heparin in a polyurethane
Release rate decreased (springtime on Atlantic coast)
Reformulated to increase release rate
Product released.
Reports of Hematoma. (Fall season)
Michael N. Helmus, Ph.D., [email protected]
Processing and heparin release cont.
In the spring, the humidity increased causing precipitation of the urethane during drying, decreasing release rate.
Reformulated during the summer.
When fall came and dry weather, no precipitation and release rate increased resulting in too high a localized heparin concentration.
Michael N. Helmus, Ph.D., [email protected]
Michael N. Helmus, Ph.D., [email protected]
Biocompatibilty of Coating
Coating concentration Cytotoxicity – Cell
Culture Rabbit Intramuscular
Implant 0% No Biocompatible
.005% Not tested Biocompatible .1% Yes Biocompatible .3% Not tested Biocompatible .5% Yes Necrosis 1.5 Yes Necrosis
Helmus, Michael N., Scott, Michael J., Enhanced Biocompatibility Coatings for Medical Implants, WO99/38547, Aug. 5, 1999
Michael N. Helmus, Ph.D., [email protected]
Intramuscular Rabbit Implants 7 days
Coating concentration > 0.5% DurafloTM
Necrosis and increased host response compared to uncoated controls
Coating concentrations< 0.3 %Biocompatible
Helmus, Michael N., Scott, Michael J., Enhanced Biocompatibility Coatings for Medical Implants, WO99/38547, Aug. 5, 1999
Ex Vivo Canine Shunt 100 ml/min flow
Bioactive Heparin Coatings
Michael N. Helmus, Ph.D., [email protected]
Metals and Metallic Alloys Passive layer durability Corrosion - pitting, fretting, stress Corrosion by-products Fracture toughness Fatigue life Stiffness compared to application Porous coatings Hypersensitivity Noble metal protein interactions; Antimicrobial activity, eg. Ag, Cu Wear
Ceramics, Inorganics, and Glasses
Bioactivity and Degree of bone formation Bioresorption rate Biostability Biodegradation by-products Fatigue and wear particulates
Michael N. Helmus, Ph.D., [email protected]
Carbons: Pyrolytic, Ultra low temp. isotropic Wear resistance Biostability Low heat of protein adsorption Thromboresistance Fatigue
Composites: Carbon fiber, nanoparticles, radioopacifiers
Surface exposure of compounded particles Extractables Hypersensitivity Residuals Lipid uptake Hydrolytic stability Biostability Biodegradation by-products Calcification Sterilization residuals Fatigue and particulates
Michael N. Helmus, Ph.D., [email protected]
Michael N. Helmus, Ph.D., [email protected]
Issues:• Stress transfer, sites of highest static and impact stress
• Conformal bearing surface – adhesion & abrasion, particles < 1 micron, osteolysis eg Total Hip• Non-conformal, hi contact stress exceeding strength of UHMWPE , subsurface delamination, pitting, fatigue cracking, particles 2-20 microns, eg Total Knee
• Abrasion of acetabular cup• Effect of gamma/ebeam sterilization on UHMWPE
• Carboxyl formation
• Fatigue life of metal stem• grain size, inclusions, wrought vs cast, surface defects
• Fatigue life of bone cement• formulation - initiator in polymer beads vs monomer• voids, inclusions, poor adhesion to stem poor filling of bone surface
Michael N. Helmus, Ph.D., [email protected]
Issues:
• Prosthesis loosening• Noncalcified tissue adjacent to cement leading to micromovement and loosening leading to stem fracture
• mechanical injury to bone during bone cement and stem placement• chemical toxicity of monomer (PMMA)• thermal injury due to exothermic reaction• hypersensitivity to bone cement• surgical technique in removing blood and debris in order to improve penetration into bone
Michael N. Helmus, Ph.D., [email protected]
Issues:
• Particles of cement leading to wear of ball and cup
• cement particles and wear particles leading to excessive inflammation and bone resorption – particles < 1 micron
•Diffuse cytoplasmic birefringence
•Citation – T. P. Schmalzried, et al, J Applied Biomaterials, Vol. 5, 185-190 (1994)
• Infection leading to bone resorption
Michael N. Helmus, Ph.D., [email protected]
Materials’ Standards for Medical ApplicationsMaterials’ Standards for Medical Applications
ASTM Standards for Materials for ASTM Standards for Materials for Medical DevicesMedical Devices
Example - Example - F 2063 – 00 Standard
Specification for Wrought Nickel-Titanium Shape Memory Alloys for Medical Devices and Surgical Implants
Michael N. Helmus, Ph.D., [email protected]
9.2 Non-metallic Inclusions and Porosity:
9.2.1 For all mill products, porosity and nonmetallic inclusions such as Ti4Ni2Ox and TiC particles shall be no larger than 12.5 µm (0.0005 in.). Furthermore, porosity and nonmetallic inclusions shall not constitute more than 1.0 % (area percent) of the structure as viewed at 400X to 500X in any field of view.
Michael N. Helmus, Ph.D., [email protected]
SEM to demonstrate
Ti2Ni(Ox)
Inclusion At Origin Of Wire
Fracture
Bend ductility and fatigue endurance limit were negatively impacted by the presence of Ti2Ni(Ox) inclusions
Michael N. Helmus, Ph.D., [email protected]
Since the failure had occurred in the cabin area,
engineers did a huge fatigue test of an actual
airplane. They varied the cabin pressure
hydraulically while they flexed the wings. After
three thousand pulsations, a crack appeared near a
cabin window and quickly spread. http://www.uh.edu/engines/
epi1773.htm
http://www.rafmuseum.org.uk/hendon/exhibitions/comet/comet5.cfm
Life Analysis – Comet Jet Experience
Michael N. Helmus, Ph.D., [email protected]
B.A.J.704 M. de Mol et al. “Non-destructive assessment of 62 Dutch Bjork-Shiley convexo-concave heart valves”
European Journal of Cardio-thoracic Surgery 11 (1997) 703–709
L. E. Eiselstein and B. James, “Medical Device Failures—Can We Learn from Our Mistakes?” Proceedings from the Materials &
Processes for Medical Devices Conference, M. Helmus, D. Medlin eds., August 25–27, 2004
Michael N. Helmus, Ph.D., [email protected]
Replacement Heart Valve Guidance - Draft Document10/14/94 • http://www.fda.gov/cdrh/ode/
3751.html
Replaced by new draft guidance: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ GuidanceDocuments/ucm193096.htm
Michael N. Helmus, Ph.D., [email protected]
Medical Mess: Implants in Jaw Joints Fail,Leaving Patients In Pain and Disfigured Teflon-Coated Disk Seemed A Boon for TMJD at First But Had Little Testing Bruce Ingersoll and Rose GutfeldStaff Reporters of The Wall Street JournalAugust 31, 1993
-TMJ disorders : arthritis, jaw and facial pain, headaches, earaches, clicking sounds in the jaw, and restricted movement.
-The prosthesis was used to replace an oval disk of cartilage
Image: http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20070916/Jaw_implants_070916/20070916?hub=Canada
Michael N. Helmus, Ph.D., [email protected]
-Prosthesis: 2 layers laminated together - a thin sheath of FEP & a wafer of highly porous Proplast: PTFE, and carbon or aluminum oxide.
-Couldn't withstand the wear and tear of the lower jaw sliding & some cases, it disintegrated within a few months.
-1974 : implants from sheets of laminated Proplast/FEP used to cover the tips of jawbones in TMJD patients.
-1979, sponge-like Proplast was endorsed by the professional society of Oral and Maxillofacial Surgeons as the "living implant" because human tissue could grow into its pores.
Michael N. Helmus, Ph.D., [email protected]
-Reported results of 50 jaw implants: "marked pain relief and restoration of jaw movement," according to a press release.
-Never tested in animal jaws before marketing. Company took the position that there was no way to reproduce in a lab animal what happens in the human TMJ.
-No human trials.
-Tests were done on a mechanical simulator that imitates the human jaw.
-Company did not test Proplast and FEP together, as a laminated product
Michael N. Helmus, Ph.D., [email protected]
-Simulator testing in an academic lab: sliding back and forth over the prosthesis with 20 pounds of force, wore through the FEP surface into the Proplast backing 100 to 200 times fasted than the wear-rate reported by the company.
-Fractured the thin FEP layer, scattered microscopic particles.
-Predicted "service life" of only one to three years.
-The company did wear-testing: FEP with a metal backing that didn't give way under the 20-pound load. Not a realistic test.
Michael N. Helmus, Ph.D., [email protected]
-Only after reports failure began in around 1984 were animal studies done. .. in dogs.
-FEP layer was "completely worn" and particles had triggered bone erosion in the dogs after a few
months. -Company contended the test showed mainly that the dog wasn't a good test animal to use.
-A study at the University of Minnesota dental school in monkeys.
-Proplast/FEP began to fragment after a year, causing "severe degenerative joint changes
Michael N. Helmus, Ph.D., [email protected]
Preclinical Efficacy and Safety Testing (Regulatory Guidelines)
Animal implantation for function and durability
Efficacy measure, e.g. repair, functional measurement
- In vivo methods - Radiology, NMR, Echo, Nuclear Medicine, Assays of Blood
- Explant analysis-- Device analysis: physical and surface-- Organ function and Viability-- Tissue histopathology
Clinical Evaluation (Regulatory
Guidelines)
Michael N. Helmus, Ph.D., [email protected]
Disruptive Technologies – New Failure Modes
Drug Delivery Therapeutic PolymersBioresorbables Tissue EngineeringStem CellsSmart Materials Imaging, eg Molecular Imaging
GenomicsProteomicsGlycomicsComputationNanoStructuresMEMS
Michael N. Helmus, Ph.D., [email protected]
Coronary Artery Disease: Drug Eluting Stents1970’s - 1980’s Bypass Surgery
1980’s Angioplasty
1990’s Stenting (The Problem: Instent Restenosis)
2000’s Drug Eluting Stents
J. Biomed. Mater. Res. 71A:625-634 (2005)
www.heartsurgery-usa.com/On_Pump_Surgery/body_on_pump_surgery.html
www.nlm.nih.gov/medlineplus/ency/presentations/100160_5.htm
www.stormontvail.org/heartcenter/patient_ed/ptca.pdf
Current Controversial Issues: Delayed endothelial Healing and Late Thrombosis
Michael N. Helmus, Ph.D., [email protected]
Proposed Solutions
- Biodegradable Coatings
-Rapidly degradable coatings and Abluminal coatings
- New Polymeric Carriers (eg ampiphilic polymers; fluorocarbon copolymers)
- Nonpolymeric carriers, eg porous and nanoporous Ceramics
- New pharmaceuticals for drug delivery coatings
- Bioctive coatings for enhanced healing
-RGD, cell adhesion proteins, GAGs, Heparin Sulfates, Biomimetic growth factors
-Endothelial progenitor and stem cell capture (eg antibodies)
Michael N. Helmus, Ph.D., [email protected]
Adverse Publicity of Nanotechnology THE DOWNSIDE OF NANOTECHNOLOGY Boston Globe
November 28, 2005 …Yet the very characteristics that make nanomaterials so promising are also sources of concern about their environmental and health risks. History is littered with technologies that once seemed benign but were discovered years later to have devastating effects on the environment. Examples include the pesticide DDT, marvelously effective at killing insects, but also, it turned out, lethal to birds of prey
like eagles, falcons, and osprey. ...
…But while the ability of some nano particles to pass through a cell could lead to breakthroughs in cancer or Alzheimer's treatment, these same features can pose environmental and health risks. Preliminary studies have shown that some
nanomaterials are able to damage skin, brain, and lung tissue. …
Nanotubes found to be as risky as asbestosMay 21, 2008
The original article is cited on the title only, and the content is ignored. It refers only to multiwalled nanotubes fabricated to the same dimensions as asbestos, not nanotubes that are being evaluated, for example, medical applications.
POLAND CA et al “Carbon nanotubes introduced into the abdominal cavity of mice show asbestos like pathogenicity in a pilot study”, online Nature Nanotechnology, May 20, 2008
Michael N. Helmus, Ph.D., [email protected]
Preclinical Safety Assessment for Nanotechnologycont’d)
Our current system is expected to identify possible hazard resulting from drug exposure, due to the extensive pre-clinical evaluation of new drugs.
For nanotechnology drugs:
Are current required studies adequate? YES
Are new testing models needed? MAYBE
http://www.fda.gov/nanotechnology/ChBSA-nanotech-presentation06-04.ppt
Michael N. Helmus, Ph.D., [email protected]
Example ofFDA guidancecovering injectable particles thatalso pertain to injectablenanoparticles
Michael N. Helmus, Ph.D., [email protected]
The Promise and the Challenge of Nano-enabled technologies for Medical Applications
Enhanced functionality and biocompatibility
Potential new paradigms required for biocompatibility and toxicity evaluations of nano-structures and particles
Michael N. Helmus, Ph.D., [email protected]
Embryonic stem cells, Bone marrow & Endothelial precursor cells
Replacing damaged myocardium and vascular tissues
Potential Failure Modes to Consider
Disease pathophysiology and aging leading to dysfunction in endogenous regenerative pathways
- Idiopathic dilated cardiomyopathy
- Atherosclerosis
- Myocardial Infarction
- Tumor angiogenesis
Stem Cell Therapies and Failure?
Michael N. Helmus, Ph.D., [email protected]
To Engineer Is Human... Therefore, Admiral Hyman G Rickover, father of the nuclear navy, “Basic Principles for Doing Your Job!”
M. N. Helmus, Details are Important, nature nanotechnology VOL 2 | SEPTEMBER 2007
Ownership: “A person doing a job —any job — must feel that he owns itand that he will remain on that jobindefinitely. …
Responsibility: “Along with Ownershipcomes the need for full acceptanceof full responsibility for the work.Shared responsibility means that noone is responsible.”
Attention to detail: “A tendency amongmanagers, particularly as they moveto higher positions, is to think theyno longer need to be concerned withdetails. If the boss is not concernedabout details, his subordinates also willnot consider them important.”
Priorities: “If you are to manage your job,you must set priorities. … You mustapply self-discipline to ensure your energyis applied where it is most needed.”
Know what is going on: “You mustestablish simple and direct means tofind out what is going on in detail in thearea of your responsibility.”
Hard work: “For this, there is nosubstitute. ....”
Checking up: “An essential element ofcarrying out my work is the need to haveit checked by an independent source.…
Facing the facts: “Another principle formanaging a successful program is to resistthe natural human inclination to hopethings will work out despite evidence ordoubt to the contrary. […] If conditionsrequire it, one must face the facts andbrutally make needed changes despiteconsiderable costs and schedule delays.”